07 Feb 22 | The International Generic and Biosimilar medicines Association (IGBA) announced that it has established a CEO Advisory Committee. Committee members represent Amneal Pharmaceuticals, Apotex, Cadila Healthcare, Cipla, Dr Reddy’s Laboratories, Insud Pharma, Lupin, Sandoz, STADA, Sun Pharmaceutical, Teva Pharmaceuticals, Towa Pharma and Viatris. IGBA announced that the Committee will provide a forum for industry leaders to discuss broad, strategic issues and to engage and position the industry on a range of critical issues.
07 Feb 22 | Biogen and Xbrane Biopharma announced that they have entered into a commercialisation and license agreement to develop, manufacture and commercialise Xcimzane™ (proposed biosimilar certolizumab pegol).
07 Feb 22 | US | Cardinal Health published its 2022 Biosimilars Report: The US Journey and Path Ahead. Cardinal predicted that 2022 is set to be a turning point for biosimilars in the US, reporting that most healthcare providers have a strong interest in using biosimilars to broaden patient access and drive more affordable care for their patients.
08 Feb 22 | ZA | South Africa’s Competition Commission filed a referral with the Competition Tribunal for prosecution of Roche for alleged excessive pricing of trastuzumab.
08 Feb 22 | Pfizer published its Q4 2021 financial results, reporting a 30% growth in biosimilars revenues year-over-year.
09 Feb 22 | RU | Selexis SA and Generium JSC announced the launch of Genolar® (biosimilar omalizumab) in Russia.
10 Feb 22 | A real-world study of Pfizer’s Zirabev® (biosimilar bevacizumab) indicates that Zirabev® has been well adopted in US oncology practice.
Pearce IP offers Australian based, generics and biosimilars focused lawyers, attorneys and regulatory affairs experts, with incomparable global experience, technical competence, and commercial elegance. Call us today on 02 9023 9988 or email info@pearceIP.law.